The Global Cytokines Market Size is projected to grow at a CAGR of 5.9% during the forecast period from 2026 to 2034 | DelveInsight

The global cytokines market was valued at USD 102 billion in 2025 and is projected to reach USD 173.50 billion by 2034. Growth is anchored in the rising burden of autoimmune and inflammatory disease, indication expansion for anti-cytokine biologics, and the emergence of engineered cytokine therapeutics.

DelveInsight's Cytokines Market Insights Report 2034 provides the current and forecast market analysis, individual leading Cytokines companies' market shares, challenges, Cytokines Market Drivers, barriers, trends, and key market Cytokines companies in the market.

To read more about the latest highlights related to the Cytokines Market @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Takeaways from the Cytokines Market Report

• In September 2024, Sanofi and Regeneron Pharmaceuticals Inc. received FDA approval for Dupixent (dupilumab) as the first biologic for adults with inadequately controlled chronic obstructive pulmonary disease with an eosinophilic phenotype. Strategic significance: extended an established anti-cytokine biologic into a major new respiratory indication, reinforcing the type 2 inflammation franchise.
• In September 2024, UCB S.A. secured FDA approvals expanding bimekizumab (Bimzelx) into psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa. Strategic significance: its dual interleukin-17A/17F mechanism positioned UCB against established interleukin-17A inhibitors.
• In April 2024, ImmunityBio Inc. received U.S. FDA approval for ANKTIVA (nogapendekin alfa inbakicept), a first-in-class interleukin-15 receptor superagonist, in combination with Bacillus Calmette-Guerin for BCG-unresponsive non-muscle invasive bladder cancer. Strategic significance: demonstrated that engineered cytokine therapeutics can succeed where native cytokines were limited by toxicity, opening a new therapeutic pathway beyond checkpoint inhibition.
• The global cytokines market is growing at a CAGR of 5.9% during the forecast period from 2026 to 2034.
• The principal drivers are the rising global prevalence of autoimmune and chronic inflammatory disease; increasing cancer incidence; continued indication expansion for anti-cytokine biologics; emergence of engineered cytokine therapeutics; expansion of biosimilar competition; growth of biomarker-guided precision medicine; and expanding use of cytokines in cell and gene therapy manufacturing.
• The leading Cytokines Companies include AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., UCB S.A., and Regeneron Pharmaceuticals Inc., among others.

To know more about why North America is leading the market growth in the Cytokines Market, Get a snapshot @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Cytokines Overview

Cytokines are small, short-lived signaling proteins secreted by immune and non-immune cells that regulate inflammation, immune activation, hematopoiesis, and tissue repair through binding to specific cell-surface receptors. As a therapeutic category, the market encompasses two complementary classes: recombinant cytokines administered as drugs (interferons, interleukins such as aldesleukin, colony-stimulating factors such as filgrastim and pegfilgrastim, and erythropoiesis-stimulating agents), and cytokine inhibitors and antagonists - monoclonal antibodies and fusion proteins that block pathogenic cytokine signaling, including tumor necrosis factor inhibitors, interleukin-17 and interleukin-23 inhibitors, interleukin-4 and interleukin-13 inhibitors, interleukin-6 inhibitors, and interleukin-1 inhibitors - which by far account for the larger revenue share. These agents underpin modern management of rheumatoid arthritis, psoriasis and psoriatic arthritis, inflammatory bowel disease, asthma, atopic dermatitis, and a widening range of immune-mediated conditions.

Cytokines Market Key Growth Drivers

• Rising global prevalence of autoimmune and chronic inflammatory diseases, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, and atopic dermatitis, is driving durable, recurring demand for anti-cytokine biologics.
• Increasing global cancer incidence - the International Agency for Research on Cancer projects a rise from 20 million new cases in 2022 to 35 million by 2050 - is driving demand for cytokine immunotherapy, including colony-stimulating factors and engineered cytokine constructs.
• Continued indication expansion for established anti-cytokine biologics, exemplified by dupilumab's 2024 approval as the first biologic for chronic obstructive pulmonary disease with an eosinophilic phenotype.
• Emergence of engineered cytokine therapeutics, including interleukin-2 muteins, interleukin-15 superagonists, and tumor-targeted immunocytokines with improved therapeutic windows, exemplified by ImmunityBio's ANKTIVA.
• Expansion of biosimilar competition following loss of exclusivity on leading tumor necrosis factor inhibitors, notably the ten approved adalimumab biosimilars in the U.S., broadening patient access and treated volume.
• Growth of biomarker-guided precision medicine, particularly the targeting of type 2 inflammation across multiple co-morbid respiratory and dermatological conditions.
• Expanding use of cytokines in cell and gene therapy manufacturing, where interleukins such as IL-2, IL-7, IL-15, and IL-21 support the expansion and activation of therapeutic immune cells.

Get a sneak peek at the Cytokines Market Dynamics @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Cytokines Market Segment Analysis

The Cytokines Market by Product Type (Tumor Necrosis Factor, Interleukins, Interferons, Colony-Stimulating Factors, and Other Cytokines), Therapeutic Application (Autoimmune and Inflammatory Disorders, Oncology, Infectious Diseases, and Others), Route of Administration (Subcutaneous, Intravenous, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Specialty and Online Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of World).

• By product type, the tumor necrosis factor (TNF) segment dominated with a 57% share in 2025.
• By therapeutic application, autoimmune and inflammatory disorders led with a 46% share in 2025.
• By route of administration, subcutaneous delivery accounted for 58% of the market in 2025.
• By distribution channel, hospital pharmacies led with a 49% share in 2025.

Which MedTech and biopharma key players in the Cytokines Market are set to emerge as the trendsetter explore @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Cytokines Companies

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson
• Novartis AG
• Sanofi
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Pfizer Inc.
• UCB S.A.
• Regeneron Pharmaceuticals Inc.
• and others.

Cytokines Market Competitive Landscape

The Cytokines market is classified as Moderately Concentrated. A group of large biopharmaceutical companies holds the anchor anti-cytokine biologic franchises that account for the majority of market value, led by AbbVie Inc., Johnson & Johnson, Novartis AG, and Eli Lilly and Company in immunology, with Sanofi and Regeneron Pharmaceuticals Inc. anchoring the type 2 inflammation franchise and Amgen Inc. strong in tumor necrosis factor and colony-stimulating factors. The market is progressively fragmenting as biosimilar developers enter the tumor necrosis factor and interleukin segments and as specialized biotechnology companies such as ImmunityBio Inc. and Nektar Therapeutics advance engineered cytokine therapeutics.

Cytokines Market Restraints

• Biosimilar-driven price erosion is compressing per-unit value in the mature segment.
• High-cost anti-cytokine biologics face restrictive prior authorization, step-therapy requirements, and statutory price negotiation.
• Anti-cytokine therapy carries risks of serious infection from immune suppression.
• Native interleukin-2 agonist cytokine therapeutics face dose-limiting toxicity, including vascular leak and cytokine release.
• Competitive intensity remains high with multiple mechanisms competing within the same indications.
• Access remains uneven in lower-income settings due to high cost and cold-chain requirements.

Interested in knowing the Cytokines Market by 2034? Click to get a snapshot of the Cytokines Market Trends @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Scope of the Cytokines Market Report

• Coverage- Global
• Forecast Period- 2026-2034
• Cytokines Companies- AbbVie Inc., Amgen Inc., Johnson & Johnson, Novartis AG, Sanofi, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Pfizer Inc., UCB S.A., and Regeneron Pharmaceuticals Inc., and others.
• Cytokines Market Restraints and Regulatory Analysis
• Cytokines Market Segmentation and Regional Assessment

Explore more information on the Cytokines Market Insights @
https://www.delveinsight.com/sample-request/cytokines-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Table of Contents

• Introduction
• Executive Summary of Cytokines Market
• Key Factors Impacting the Cytokines Market
• Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
• Regulatory Analysis
• Porter's Five Forces Analysis
• Cytokines Market Assessment
• Cytokines Market Competitive Landscape
• Cytokines Market Startup Funding and Investment Trends
• Cytokines Market Company and Product Profiles
• Cytokines Report KOL Views
• Project Approach
• About DelveInsight
• Disclaimer and Contact Us

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.